Your browser is no longer supported. Please, upgrade your browser.
Galmed Pharmaceuticals Ltd.
Index- P/E- EPS (ttm)-1.44 Insider Own14.14% Shs Outstand23.37M Perf Week-4.60%
Market Cap63.00M Forward P/E- EPS next Y-1.40 Insider Trans0.00% Shs Float21.57M Perf Month-18.09%
Income-31.60M PEG- EPS next Q-0.38 Inst Own23.80% Short Float3.01% Perf Quarter-23.62%
Sales- P/S- EPS this Y-39.50% Inst Trans0.18% Short Ratio2.35 Perf Half Y-32.70%
Book/sh2.27 P/B1.10 EPS next Y6.00% ROA-53.20% Target Price- Perf Year-48.87%
Cash/sh2.32 P/C1.07 EPS next 5Y20.00% ROE-60.00% 52W Range2.15 - 6.25 Perf YTD-19.94%
Dividend- P/FCF- EPS past 5Y-7.20% ROI- 52W High-60.16% Beta2.18
Dividend %- Quick Ratio8.40 Sales past 5Y- Gross Margin- 52W Low15.81% ATR0.14
Employees18 Current Ratio8.40 Sales Q/Q- Oper. Margin- RSI (14)37.34 Volatility5.02% 5.32%
OptionableYes Debt/Eq0.00 EPS Q/Q-32.90% Profit Margin- Rel Volume0.23 Prev Close2.51
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume275.60K Price2.49
Recom1.80 SMA20-9.65% SMA50-13.95% SMA200-26.06% Volume62,411 Change-0.80%
May-22-20Downgrade B. Riley FBR Buy → Neutral $11 → $8
Feb-04-20Initiated Craig Hallum Buy $18
Jan-30-20Resumed Cantor Fitzgerald Overweight $9 → $14
Dec-02-19Initiated Canaccord Genuity Buy
Dec-12-18Initiated B. Riley FBR Buy $28
Aug-02-18Reiterated Maxim Group Buy $30 → $27
Jul-13-18Initiated Stifel Buy $35
Jul-12-18Initiated Cantor Fitzgerald Overweight $59
Jun-12-18Reiterated H.C. Wainwright Buy $24 → $43
Mar-15-18Upgrade Maxim Group Hold → Buy $14
Feb-14-18Downgrade Maxim Group Buy → Hold
Feb-12-18Reiterated H.C. Wainwright Buy $18 → $24
Nov-15-17Initiated ROTH Capital Buy $32
Aug-08-17Reiterated H.C. Wainwright Buy $12 → $18
Jul-31-17Reiterated Maxim Group Buy $9 → $14
Aug-01-16Reiterated Maxim Group Buy $24 → $9
Jul-06-16Resumed ROTH Capital Buy $6
Mar-28-16Resumed H.C. Wainwright Buy $22
Jun-23-15Initiated H.C. Wainwright Buy $21
May-06-15Initiated Sun Trust Rbsn Humphrey Buy $20
Jul-29-21 08:30AM  
Jun-04-21 06:57AM  
May-13-21 07:50AM  
May-06-21 08:30AM  
May-03-21 08:30AM  
Mar-19-21 07:23AM  
Mar-18-21 07:00AM  
Mar-16-21 08:00AM  
Mar-11-21 08:30AM  
Feb-16-21 09:29AM  
Feb-11-21 11:16AM  
Feb-04-21 01:30AM  
Jan-26-21 08:00AM  
Jan-19-21 08:00AM  
Dec-17-20 07:00AM  
Dec-04-20 09:08AM  
Nov-12-20 07:00AM  
Nov-10-20 08:40AM  
Nov-09-20 08:00AM  
Nov-05-20 08:30AM  
Oct-20-20 08:31AM  
Sep-10-20 08:49AM  
Aug-06-20 07:00AM  
Jul-30-20 08:30AM  
Jul-22-20 10:34AM  
Jul-14-20 05:31PM  
Jul-06-20 07:55AM  
Jun-26-20 06:42AM  
Jun-10-20 08:34AM  
May-14-20 05:31PM  
May-07-20 08:30AM  
May-02-20 09:36AM  
Mar-26-20 09:40PM  
Mar-12-20 07:00AM  
Mar-05-20 08:30AM  
Feb-28-20 09:30AM  
Feb-05-20 04:11PM  
Jan-03-20 08:25AM  
Dec-14-19 07:21PM  
Dec-04-19 09:26AM  
Nov-29-19 08:41AM  
Nov-08-19 10:57PM  
Nov-06-19 07:00AM  
Nov-04-19 09:10AM  
Oct-31-19 08:30AM  
Oct-30-19 08:30AM  
Sep-26-19 08:00AM  
Sep-19-19 01:05PM  
Aug-12-19 04:33AM  
Aug-05-19 07:00AM  
Jul-29-19 08:30AM  
Jul-24-19 01:17PM  
May-23-19 12:37PM  
May-07-19 08:25AM  
Apr-30-19 08:30AM  
Apr-09-19 07:30AM  
Mar-13-19 08:25AM  
Mar-12-19 10:02AM  
Mar-06-19 08:30AM  
Dec-28-18 04:52PM  
Dec-12-18 02:26PM  
Dec-11-18 09:22AM  
Nov-20-18 08:45AM  
Nov-14-18 07:50AM  
Nov-13-18 11:30AM  
Nov-05-18 08:45AM  
Oct-31-18 03:38PM  
Oct-29-18 08:30AM  
Oct-12-18 03:21PM  
Oct-02-18 08:39AM  
Sep-27-18 08:00AM  
Aug-02-18 05:40PM  
Jul-26-18 08:30AM  
Jul-20-18 11:42AM  
Jul-13-18 07:02PM  
Jul-12-18 12:11PM  
Jun-26-18 07:06AM  
Jun-25-18 07:30AM  
Jun-20-18 08:36AM  
Jun-19-18 09:37PM  
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.